We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Billon have created a technology that enables zero cost global payments by the use of a simple mobile app. Billon's mobile app allows you to instantly pay for the rest of an article from the Guardian or even donate to your favourite Youtubers with a few clicks of a button. 
days to go: Expired investment: £1,406,667
Findr aims to automate the creation of business partnerships by providing easy access to hyper-targeted opportunities in minutes. The company asserts that its platform allows any business, regardless of its size, to sign up, post its partnership requirements, and explore opportunities for free. The company's portal allows users to request a 1-hour 'Discovery' call with a potential partner when the said user spots a relevant opportunity. Findr argues that it has made 'Discovery' for free for the first few months to build its user base. The company has onboarded 140 business users ranging from early-stage to global brands such as Mastercard, Uber and Visa since November 2020. Findr has featured in Forbes for helping businesses navigate COVID-19. The company will use the investment to develop two new price plans – Unlimited and Enterprise, introduce new platform features, hire a machine learning expert, and undertake digital activity to grow its user base.

Pitch Rated

51%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £396,288
iDal is an employer platform on a mission to disrupt the inefficient talent management world. The company argues that the talent management industry is outdated and resistant to new technologies, increasing frustration for talent and clients. iDal aims to change this. It has onboarded over 300 talented models to date, including one of the world's top 50 models Ajak Deng and influencers such as @Saufeeya on its portal. It has also worked with notable names in fashion like Vogue, Burberry, Urban Outfitters, etc. The company asserts that its platform allows one agent to do the job of five, reducing the time spent on admin and negotiation, boosting an agent's ability to nurture talent and deliver the best client service. iDal is seeking an investment of £400,000 to invest in promoting its models and hiring three new agents.
days to go: Expired investment: £408,080
A foreign currency exchange company operating since 2005 with over 6500 customers. EuroXChanger are now seeking investment to expand the business from three locations to twelve, as well as fund development for a mobile app to allow customers to transfer monies more efficiently and conveniently.
days to go: Expired investment: £51,680
Growth Capital Ventures (GCV) is a Financial Conduct Authority (FCA) approved fintech company. GCV's mission is to back the game changers, innovators and value creators. It is operating at three different levels namely, G-Ventures, a specialist software development division; Quva, a private investor network; and G- Labs, an innovation lab. The company aims to provide investors with access to well researched alternative investment opportunities that are selected for their potential to deliver better returns than traditional mainstream investment products. GCV has structured property transactions worth £14.7 million, has 5000+ everyday investors, and seen 500+ jobs created by portfolio companies. GCV will use the investment to grow its business across different verticals. 
days to go: Expired investment: £1,295,410
Recap is a cryptocurrency portfolio tracking, analytics and tax reporting platform. The company claims that market participants engaging in cryptocurrency have to deal with complex issues such as tracking all of their transactions, valuing cryptocurrency transactions in their tax currency and understanding capital gains tax legislation laws. Recap aims to solve this issue by enabling said participants to calculate any tax they owe on their cryptocurrency trading activity in a matter of seconds on its portal. The company has plans to launch a mobile application enabling investors to track their portfolio on the move. It also intends to come up with a Business-to-business (B2B) offering which Recap asserts will enable crypto native companies to account for their cryptocurrency activity with automatic accounts reconciliation to accounting software like Xero and Quickbooks. The company’s exit strategy is a trade sale within 3-5 years to a cryptocurrency exchange or accounting software provider.

Pitch Rated

84%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £120,472
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph